Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $39.18

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned an average rating of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $39.1818.

A number of analysts have commented on STOK shares. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research report on Monday, January 5th. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Guggenheim initiated coverage on Stoke Therapeutics in a report on Thursday, February 5th. They set a “buy” rating and a $60.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 5th.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $31.91 on Tuesday. Stoke Therapeutics has a one year low of $5.35 and a one year high of $38.69. The company has a market cap of $1.82 billion, a PE ratio of 47.63 and a beta of 1.10. The firm’s 50 day simple moving average is $31.59 and its 200 day simple moving average is $27.18.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 3,662 shares of Stoke Therapeutics stock in a transaction on Friday, December 5th. The shares were sold at an average price of $31.34, for a total value of $114,767.08. Following the completion of the sale, the insider owned 19,798 shares of the company’s stock, valued at approximately $620,469.32. This trade represents a 15.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Jonathan Allan sold 8,785 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $31.29, for a total transaction of $274,882.65. Following the transaction, the general counsel owned 15,809 shares in the company, valued at approximately $494,663.61. The trade was a 35.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 58,302 shares of company stock worth $1,826,430. Corporate insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently added to or reduced their stakes in STOK. Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics during the 4th quarter worth approximately $26,000. Harbour Investments Inc. boosted its position in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new stake in Stoke Therapeutics during the third quarter worth $41,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after buying an additional 658 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.